ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 03:30PM GMT
Release Date Price: $23.63 (+1.46%)
Charles Cliff Duncan
Cantor Fitzgerald & Co., Research Division - Research Analyst

I'm Charles Duncan. I'm a biotech analyst with Cantor, and it's a pleasure to introduce the next presenting company, ACADIA Pharmaceuticals for the Cantor Global Healthcare Conference in 2023. ACADIA is a company that I have covered for a long time, about a decade or more, and know it quite well. It's an interesting, what I consider, neuro innovator, which has long had a drug for the treatment, the only drug that's approved for the treatment of psychosis associated with Parkinson's disease.

But it has seen a very interesting, I think interesting, evolution in its business with the approval of the first drug ever for the rare developmental neurological disease called the Rett syndrome. And so it's a pleasure to introduce Mark Schneyer, the company's Chief Financial Officer. Mark, thank you for joining.

Mark C. Schneyer;Charles Cliff Duncan
ACADIA Pharmaceuticals Inc. - Executive VP & CFO;Cantor Fitzgerald

Thanks for having us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot